UroGen Pharma (URGN) Cash & Equivalents (2016 - 2026)
UroGen Pharma (URGN) reported Cash & Equivalents of $79.13 million for Q2 2026, down 14.8% from $92.9 million a year earlier and down 28.0% from the prior quarter.
Powered by 
Analysis
UroGen Pharma (URGN) Cash & Equivalents (2016 - 2026) Analysis & Trends
At the end of FY2025, UroGen Pharma posted Cash & Equivalents of $110.75 million, down 35.6% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of 15.9% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $171.99 million in FY2024 (+81.0%), $95 million in FY2023 (+71.5%), $55.41 million in FY2022 (+24.9%) and $44.36 million in FY2021 (-16.1%).
- The Q2 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q2 2023.
- Year over year, Cash & Equivalents gained in three of the last eight quarters, with an average decline of 8.2%.
- The high point for year-over-year Cash & Equivalents in five years was Q2 2024 (growth of 992.9%); the low point was Q2 2023 (a decline of 75.1%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $109.97 million (Q1 2026), $110.75 million (Q4 2025) and $90.04 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | UroGen Pharma | 2.02 Bn | 1.53 Bn | 65.88 Mn | 79.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.13 Mn |
| Mar 31, 2026 | 109.97 Mn |
| Dec 31, 2025 | 110.75 Mn |
| Sep 30, 2025 | 90.04 Mn |
| Jun 30, 2025 | 92.90 Mn |
| Mar 31, 2025 | 104.03 Mn |
| Dec 31, 2024 | 171.99 Mn |
| Sep 30, 2024 | 124.92 Mn |
| Jun 30, 2024 | 219.97 Mn |
| Mar 31, 2024 | 131.44 Mn |
| Dec 31, 2023 | 95.00 Mn |
| Sep 30, 2023 | 119.31 Mn |
| Jun 30, 2023 | 20.13 Mn |
| Mar 31, 2023 | 36.54 Mn |
| Dec 31, 2022 | 55.41 Mn |
| Sep 30, 2022 | 28.69 Mn |
| Jun 30, 2022 | 80.69 Mn |
| Mar 31, 2022 | 105.38 Mn |
| Dec 31, 2021 | 44.36 Mn |
| Sep 30, 2021 | 55.34 Mn |
API Access
UroGen Pharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=URGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "URGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=URGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();